Back to mobile site
Get it on Google Play

Arbutus receives FDA fast track status for hepatitis B drug imdusiran

April 15, 2026 7:30 AM EDT Send to a Friend
Arbutus Biopharma Corporation (NASDAQ: ABUS) announced that the U.S. Food and Drug Administration has granted Fast Track designation for imdusiran ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login